Back to search

Article

Lenalidomide enhances CD19 CAR-T cell fitness and target-cell engagement in relapsed/refractory CLL

2026-07-01

Abstract excerpt

<h4>Background</h4> CD19-directed CAR-T cell therapy can induce durable remissions in chronic lymphocytic leukemia (CLL), but response rates are lower than in other B-cell malignancies, in part because CLL is characterized by T-cell dysfunction, defective immune synapse formation, and impaired target-cell co-stimulation. Lenalidomide is an immunomodulatory drug with the potential to act on both sides of the CAR-T...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3b1cca10-eb88-5944-9632-31ba253bd1f5
DOI
10.64898/2026.06.23.26356089
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Lenalidomide enhances CD19 CAR-T cell fitness and target-cell engagement in relapsed/refractory CLLDOI 10.64898/2026.06.23.26356089
Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphomaSemantic proximity
Pomalidomide enhances CAR-T cell therapeutic efficacy and Remodels Immune Microenvironment in Lymphoid MalignanciesSemantic proximity
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B-cell lymphomaSemantic proximity
Tandem CD19/CD22 CAR-T cells conquer high-risk cytogenetics and acquire complete remission in r/r B-ALL patientsSemantic proximity
CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphomaSemantic proximity
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphomaSemantic proximity
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.Semantic proximity
A distinct CAR-T cell phenotype mediates therapeutic response at limited doses.Semantic proximity
Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignanciesSemantic proximity
Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trialSemantic proximity
Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.Semantic proximity
The CD19-4-1BBL antibody fusion protein unleashes the immune system against high-risk chronic lymphocytic leukemiaSemantic proximity
Select a neighboring publication to make it the new centre.